DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Sang-Oh | ko |
dc.contributor.author | Shin, Sejeong | ko |
dc.contributor.author | Lee, Ho-Jae | ko |
dc.contributor.author | Chun, Hyo-Kon | ko |
dc.contributor.author | Chung, An Sik | ko |
dc.date.accessioned | 2013-03-06T12:08:12Z | - |
dc.date.available | 2013-03-06T12:08:12Z | - |
dc.date.created | 2012-02-06 | - |
dc.date.created | 2012-02-06 | - |
dc.date.issued | 2006-11 | - |
dc.identifier.citation | MOLECULAR CANCER THERAPEUTICS, v.5, no.11, pp.2666 - 2675 | - |
dc.identifier.issn | 1535-7163 | - |
dc.identifier.uri | http://hdl.handle.net/10203/86943 | - |
dc.description.abstract | Matrix metalloproteinase (MMP)-9 plays a key role in tumor invasion. Inhibitors of MMP-9 were screened from Metasequoia glyptostroboides (Dawn redwood) and one potent inhibitor, isoginkgetin, a biflavonoid, was identified. Noncytotoxic levels of isoginkgetin decreased MMP-9 production profoundly, but up-regulated the level of tissue inhibitor of metalloproteinase (TIMP)-1, an inhibitor of MMP-9, in HT1080 human fibrosarcoma cells. The major mechanism of Ras-dependent MMP-9 production in HT1080 cells was phosphatidylinositol 3-kinase (PI3K)/Akt/nuclear factor-rB (NF-KB) activation. Expression of dominant-active H-Ras and p85 (a subunit of PI3K) increased MMP-9 activity, whereas dominant-negative forms of these molecules decreased the level of MMP-9. H-Ras did not increase MMP-9 in the presence of a PI3K inhibitor, LY294002, and a NF-kappa B inhibitor, SN50. Further studies showed that isoginkgetin regulated MMP-9 production via PI3K/Akt/NF-kappa B pathway, as evidenced by the findings that isoginkgetin inhibited activities of both Akt and NF-kappa B. PI3K/Akt is a well-known key pathway for cell invasion, and isoginkgetin inhibited HT1080 tumor cell invasion substantially. Isoginkgetin was also quite effective in inhibiting the activities of Akt and MMP-9 in MDA-MB-231 breast carcinomas and B16F10 melanoma. Moreover, isoginkgetin treatment resulted in marked decrease in invasion of these cells. In summary, PI3K/Akt is a major pathway for MMP-9 expression and isoginkgetin markedly decreased MMP-9 expression and invasion through inhibition of this pathway. This suggests that isoginkgetin could be a potential candidate as a therapeutic agent against tumor invasion. | - |
dc.language | English | - |
dc.publisher | Amer Assoc Cancer Research | - |
dc.subject | HUMAN TISSUE INHIBITOR | - |
dc.subject | GINKGO-BILOBA LEAVES | - |
dc.subject | MATRIX METALLOPROTEINASES | - |
dc.subject | ACTIVATOR PROTEIN-1 | - |
dc.subject | CANCER PREVENTION | - |
dc.subject | TIMP-1 GENE | - |
dc.subject | MAP KINASE | - |
dc.subject | PROMOTER | - |
dc.subject | FIBROBLASTS | - |
dc.subject | PROGRESSION | - |
dc.title | Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression | - |
dc.type | Article | - |
dc.identifier.wosid | 000242138000008 | - |
dc.identifier.scopusid | 2-s2.0-33845200847 | - |
dc.type.rims | ART | - |
dc.citation.volume | 5 | - |
dc.citation.issue | 11 | - |
dc.citation.beginningpage | 2666 | - |
dc.citation.endingpage | 2675 | - |
dc.citation.publicationname | MOLECULAR CANCER THERAPEUTICS | - |
dc.identifier.doi | 10.1158/1535-7163.MCT-06-0321 | - |
dc.contributor.nonIdAuthor | Yoon, Sang-Oh | - |
dc.contributor.nonIdAuthor | Shin, Sejeong | - |
dc.contributor.nonIdAuthor | Lee, Ho-Jae | - |
dc.contributor.nonIdAuthor | Chun, Hyo-Kon | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | HUMAN TISSUE INHIBITOR | - |
dc.subject.keywordPlus | GINKGO-BILOBA LEAVES | - |
dc.subject.keywordPlus | MATRIX METALLOPROTEINASES | - |
dc.subject.keywordPlus | ACTIVATOR PROTEIN-1 | - |
dc.subject.keywordPlus | CANCER PREVENTION | - |
dc.subject.keywordPlus | TIMP-1 GENE | - |
dc.subject.keywordPlus | MAP KINASE | - |
dc.subject.keywordPlus | PROMOTER | - |
dc.subject.keywordPlus | FIBROBLASTS | - |
dc.subject.keywordPlus | PROGRESSION | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.